- DC260126
-
- $144.00
-
2026-08-19
- CAS:346692-04-4
- Purity: 99.77%
- Supply Ability: 10g
|
| | N-(4-butylphenyl)-4-fluorobenzenesulfonamide Basic information |
| Product Name: | N-(4-butylphenyl)-4-fluorobenzenesulfonamide | | Synonyms: | N-(4-butylphenyl)-4-fluorobenzenesulfonamide;DC260126;DC-260126 ;DC 260126;Benzenesulfonamide, N-(4-butylphenyl)-4-fluoro-;DC260126 >=98% (HPLC);stress,DC260126,DC-260126,FFAR,Inhibitor,insulin,inhibit,secretion,Apoptosis,DC 260126,Free Fatty Acid Receptor,phosphorylation,elevation,Ca2+;DC260126 ，S0742;DC260126 | | CAS: | 346692-04-4 | | MF: | C16H18FNO2S | | MW: | 307.38 | | EINECS: | | | Product Categories: | | | Mol File: | 346692-04-4.mol |  |
| | N-(4-butylphenyl)-4-fluorobenzenesulfonamide Chemical Properties |
| storage temp. | -20°C | | solubility | DMSO: soluble20mg/mL, clear | | form | powder | | color | white to beige | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. | | InChI | 1S/C16H18FNO2S/c1-2-3-4-13-5-9-15(10-6-13)18-21(19,20)16-11-7-14(17)8-12-16/h5-12,18H,2-4H2,1H3 | | InChIKey | CNGHPXKWPGIDSK-UHFFFAOYSA-N | | SMILES | Fc1ccc(cc1)[S](=O)(=O)Nc2ccc(cc2)CCCC |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | N-(4-butylphenyl)-4-fluorobenzenesulfonamide Usage And Synthesis |
| Description | DC260126 is a free fatty acid receptor 1 (FFAR1/GPR40) antagonist that inhibits GPR40-mediated Ca2+ elevations stimulated by linoleic, oleic, palmitoleic, and lauric acid (Item Nos. 90150, 90260, 10009871, and 10006626, respectively) with IC50 values of 6.28, 5.96, 7.07, and 4.58 μM, respectively. At 10 mg/kg, it has been shown to inhibit glucose-stimulated insulin secretion, to reduce blood insulin levels, to improve insulin sensitivity, and to decrease the rate of pancreatic β-cell apoptosis in obese diabetic db/db mice. | | Uses | DC260126 is a potent antagonist of GPR40 (FFAR1). DC260126 dose-dependently inhibits GPR40-mediated Ca2+ elevations stimulated by linoleic acid, oleic acid, palmitoleic acid and lauric acid (IC50: 6.28, 5.96, 7.07, 4.58 μM, respectively)[1]. DC260126 could protect MIN6 β cells from palmitate-induced ER stress and apoptosis[2]. | | storage | Store at -20°C | | References | [1] HUI HU . A novel class of antagonists for the FFAs receptor GPR40[J]. Biochemical and biophysical research communications, 2009, 390 3: Pages 557-563. DOI:10.1016/j.bbrc.2009.10.004
[2] XIAODONG ZHANG . DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats[J]. Biomedicine & Pharmacotherapy, 2010, 64 9: Pages 647-651. DOI:10.1016/j.biopha.2010.06.008
[3] PENG SUN. DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic β-Cells dysfunction in db/db mice.[J]. PLoS ONE, 2013: e66744. DOI:10.1371/journal.pone.0066744
[4] JINWEI WU. Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis[J]. Journal of cellular biochemistry, 2011, 113 4: 1152-1158. DOI:10.1002/jcb.23450 |
| | N-(4-butylphenyl)-4-fluorobenzenesulfonamide Preparation Products And Raw materials |
|